Clinical Research
Our Clinical Trials Learn more about our investigational approaches for colorectal cancer 
|
|
|
Memorial Sloan-Kettering research helped establish the effectiveness of irinotecan, a drug now approved for the initial treatment of metastatic colorectal cancer when given with 5-fluorouracil and leucovorin, and for patients with metastatic colorectal cancer that has persisted or returned despite prior chemotherapy.
Our investigators also led studies leading to the approval of the drugs oxaliplatin and cetuximab. Oxaliplatin is now commonly used, along with 5-fluorouracil and leucovorin (a regimen called FOLFOX), to treat stage III colorectal cancer that has been surgically removed, as well as for stage IV (metastatic) colorectal cancer. The drug has been shown to slow cancer growth, reduce the risk of recurrence, and (in some patients) improve survival. Cetuximab is a drug used alone or in combination with irinotecan to slow disease progression in patients with metastatic colorectal cancer.
New Technologies for Advanced Cancers
The liver is a common site for colorectal cancer to spread. For patients whose disease has spread to the liver, chemotherapy delivered directly to the liver can shrink tumors more effectively than that given through a vein in the arm. Memorial Sloan-Kettering has an active program developing new technologies to deliver chemotherapy through a pump placed directly into the hepatic artery, which leads to the liver.
For patients with tumor spread to a few sites in the liver or lung, thermal ablation can sometimes be applied to burn or freeze tumors with a small needle. These techniques include radiofrequency ablation, microwave ablation, and cryoablation. Our team is also investigating the role of newer techniques to safely destroy cancer with tools such as irreversible electroporation (the "NanoKnife"). A National Institutes of Health-funded study is analyzing tissue from the ablation zone to see if this approach can facilitate the early identification of patients at risk for tumor recurrence after treatment.